Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jeffrey D. Fuller is active.

Publication


Featured researches published by Jeffrey D. Fuller.


BMC Infectious Diseases | 2007

Multi-drug resistant Acinetobacter infections in critically injured Canadian forces soldiers.

Homer C. Tien; Anthony Battad; Elizabeth Bryce; Jeffrey D. Fuller; Michael R. Mulvey; Kathy Bernard; Ronald Brisebois; Jay Doucet; Sandro Rizoli; Robert Fowler; Andrew E. Simor

BackgroundMilitary members, injured in Afghanistan or Iraq, have returned home with multi-drug resistant Acinetobacter baumannii infections. The source of these infections is unknown.MethodsRetrospective study of all Canadian soldiers who were injured in Afghanistan and who required mechanical ventilation from January 1 2006 to September 1 2006. Patients who developed A. baumannii ventilator associated pneumonia (VAP) were identified. All A. baumannii isolates were retrieved for study patients and compared with A. baumannii isolates from environmental sources from the Kandahar military hospital using pulsed-field gel electrophoresis (PFGE).ResultsDuring the study period, six Canadian Forces (CF) soldiers were injured in Afghanistan, required mechanical ventilation and were repatriated to Canadian hospitals. Four of these patients developed A. baumannii VAP. A. baumannii was also isolated from one environmental source in Kandahar – a ventilator air intake filter. Patient isolates were genetically indistinguishable from each other and from the isolates cultured from the ventilator filter. These isolates were resistant to numerous classes of antimicrobials including the carbapenems.ConclusionThese results suggest that the source of A. baumannii infection for these four patients was an environmental source in the military field hospital in Kandahar. A causal linkage, however, was not established with the ventilator. This study suggests that infection control efforts and further research should be focused on the military field hospital environment to prevent further multi-drug resistant A. baumannii infections in injured soldiers.


Infection and Immunity | 2001

Streptococcus iniae Virulence Is Associated with a Distinct Genetic Profile

Jeffrey D. Fuller; Darrin J. Bast; Victor Nizet; Donald E. Low; Joyce de Azavedo

ABSTRACT Streptococcus iniae causes meningoencephalitis and death in commercial fish species and has recently been identified as an emerging human pathogen producing fulminant soft tissue infection. As identified by pulsed-field gel electrophoresis (PFGE), strains causing disease in either fish or humans belong to a single clone, whereas isolates from nondiseased fish are genetically diverse. In this study, we used in vivo and in vitro models to examine the pathogenicity of disease-associated isolates. Strains with the clonal (disease-associated) PFGE profile were found to cause significant weight loss and bacteremia in a mouse model of subcutaneous infection. As little as 102 CFU of a disease-associated strain was sufficient to establish bacteremia, with higher inocula (107) resulting in increased mortality. In contrast, non-disease-associated (commensal) strains failed to cause bacteremia and weight loss, even at inocula of 108 CFU. In addition, disease-associated strains were more resistant to phagocytic clearance in a human whole blood killing assay compared to commensal strains, which were almost entirely eradicated. Disease-associated strains were also cytotoxic to human endothelial cells as measured by lactate dehydrogenase release from host cells. However, both disease-associated and commensal strains adhered to and invaded cultured human epithelial and endothelial cells equally well. While cellular invasion may still contribute to the pathogenesis of invasive S. iniaedisease, resistance to phagocytic clearance and direct cytotoxicity appear to be discriminating virulence attributes of the disease-associated clone.


Journal of Antimicrobial Chemotherapy | 2013

Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007–11 study

George G. Zhanel; Heather J. Adam; Melanie R. Baxter; Jeffrey D. Fuller; Kimberly A. Nichol; Andrew Denisuik; Philippe Lagacé-Wiens; Andrew Walkty; James A. Karlowsky; Frank Schweizer; Daryl J. Hoban

OBJECTIVESnThe purpose of the CANWARD study was to assess the antimicrobial activity of a variety of available agents against 22,746 pathogens isolated from patients in Canadian hospitals between 2007 and 2011.nnnMETHODSnBetween 2007 and 2011, 27,123 pathogens were collected from tertiary-care centres from across Canada; 22,746 underwent antimicrobial susceptibility testing using CLSI broth microdilution methods. Patient demographic data were also collected.nnnRESULTSnOf the isolates collected, 45.2%, 29.6%, 14.8% and 10.4% were from blood, respiratory, urine and wound specimens, respectively. Patient demographics were as follows: 54.4%/45.6% male/female, 12.8% ≤ 17 years old, 45.1% 18-64 years old and 42.1% ≥65 years old. Isolates were obtained from patients in medical and surgical wards (37.8%), emergency rooms (25.7%), clinics (18.0%) and intensive care units (18.5%). The three most common pathogens were Escherichia coli (20.1%), Staphylococcus aureus [methicillin-susceptible S. aureus and methicillin-resistant S. aureus (MRSA)] (20.0%) and Pseudomonas aeruginosa (8.0%), which together accounted for nearly half of the isolates obtained. Susceptibility rates (SRs) for E. coli were 100% meropenem, 99.9% tigecycline, 99.7% ertapenem, 97.7% piperacillin/tazobactam, 93.7% ceftriaxone, 90.5% gentamicin, 77.9% ciprofloxacin and 73.4% trimethoprim/sulfamethoxazole. Twenty-three percent of the S. aureus were MRSA. SRs for MRSA were 100% daptomycin, 100% linezolid, 100% telavancin, 99.9% vancomycin, 99.8% tigecycline, 92.2% trimethoprim/sulfamethoxazole and 48.2% clindamycin. SRs for P. aeruginosa were 90.1% amikacin, 93.1% colistin, 84.0% piperacillin/tazobactam, 83.5% ceftazidime, 82.6% meropenem, 72.0% gentamicin and 71.9% ciprofloxacin.nnnCONCLUSIONSnThe CANWARD surveillance study has provided important data on the antimicrobial susceptibility of pathogens commonly causing infections in Canadian hospitals.


Infection and Immunity | 2002

Identification of a streptolysin S-associated gene cluster and its role in the pathogenesis of Streptococcus iniae disease

Jeffrey D. Fuller; Alvin C. Camus; Carla Duncan; Victor Nizet; Darrin J. Bast; Ronald L. Thune; Donald E. Low; Joyce De Azavedo

ABSTRACT Streptococcus iniae causes meningoencephalitis and death in cultured fish species and soft-tissue infection in humans. We recently reported that S. iniae is responsible for local tissue necrosis and bacteremia in a murine subcutaneous infection model. The ability to cause bacteremia in this model is associated with a genetic profile unique to strains responsible for disease in fish and humans (J. D. Fuller, D. J. Bast, V. Nizet, D. E. Low, and J. C. S. de Azavedo, Infect. Immun. 69:1994-2000, 2001). S. iniae produces a cytolysin that confers a hemolytic phenotype on blood agar media. In this study, we characterized the genomic region responsible for S. iniae cytolysin production and assessed its contribution to virulence. Transposon (Tn917) mutant libraries of commensal and disease-associated S. iniae strains were generated and screened for loss of hemolytic activity. Analysis of two nonhemolytic mutants identified a chromosomal locus comprising 9 genes with 73% homology to the group A streptococcus (GAS) sag operon for streptolysin S (SLS) biosynthesis. Confirmation that the S. iniae cytolysin is a functional homologue of SLS was achieved by PCR ligation mutagenesis, complementation of an SLS-negative GAS mutant, and use of the SLS inhibitor trypan blue. SLS-negative sagB mutants were compared to their wild-type S. iniae parent strains in the murine model and in human whole-blood killing assays. These studies demonstrated that S. iniae SLS expression is required for local tissue necrosis but does not contribute to the establishment of bacteremia or to resistance to phagocytic clearance.


Journal of Clinical Microbiology | 2012

Comparison of the Hybrid Capture 2 and cobas 4800 Tests for Detection of High-Risk Human Papillomavirus in Specimens Collected in PreservCyt Medium

Anita A. Wong; Jeffrey D. Fuller; Kanti Pabbaraju; Sallene Wong; George Zahariadis

ABSTRACT Clinical cervical cytology specimens (n = 466) collected in PreservCyt (Hologic Inc.) were used to evaluate the agreement between Hybrid Capture 2 (hc2; Qiagen) and cobas 4800 (c4800; Roche Molecular Diagnostics) for the detection of high-risk human papillomavirus (HR HPV) genotype infections. The agreement between the two assays was 93.8% (kappa = 0.87; 95% confidence interval, 0.828 to 0.918), with 186 and 251 concordant positive and negative results, respectively. All 186 concordant positives were confirmed using the Linear Array (LA; Roche Molecular Diagnostics) genotyping test. Of the 29 samples with discordant results (6.2%), 18 were hc2 positive and LA verified 17 as positive for HR HPV. Eleven discordant specimens were c4800 positive, and LA confirmed 5 as positive for HR HPV. As of October 2009, practice guidelines in Alberta, Canada, recommend reflex HPV testing for women over 30 years old with atypical squamous cells of undetermined significance (ASCUS) and for women over 50 years old with low-grade squamous intraepithelial lesions (LSIL) to help prioritize those who should undergo further evaluation. In this study, agreement between hc2 and c4800 results for samples from women over 30 years old with ASCUS cytology was 92.3% (n = 13), while no samples from women over 50 years old with LSIL cytology were identified for analysis.


Journal of Clinical Microbiology | 2009

Interpretation of MRSASelect Screening Agar at 24 Hours of Incubation

Julie Carson; Betty Lui; Linda Rosmus; Howard Rennick; Jeffrey D. Fuller

An incubation time of 24 h at 35 to 38°C is recommended for the optimal performance of MRSASelect (Bio-Rad) chromogenic screening agar. An additional 24 h is required to capture slow-growing methicillin-resistant Staphylococcus aureus (MRSA). However, the normal hours of operation for most laboratories cannot reliably accommodate 24-h interpretation intervals. Daily agar plate interpretations are more likely to occur around 18 h and 42 h of incubation, which may compromise the performance of the chromogenic agar and negatively impact patient infection control efforts. In order to validate the importance of stringent incubation times to plate performance, we evaluated MRSASelect medium at controlled intervals of 24 and 48 h of incubation, using clinical MRSA-screening swabs. A total of 1,071 MRSA-positive and 2,733 MRSA-negative cultures were selected for analysis. Compared to 48-h-incubation results, the sensitivity and specificity of MRSASelect at 24 h were 98.3% and 98.2%, respectively. Only 19 of 1,071 (1.8%) MRSA-positive isolates required 48 h for detection. Holding 24-h negative plates an additional 24 h resulted in the workup of 253 (6.6%) pink, yet non-MRSA, colonies. The 24-h positive and negative predictive values of MRSASelect, assuming MRSA prevalences of 1, 5, and 10%, were 35.5 and 99.98%, 74.2 and 99.9%, and 85.9 and 99.8%, respectively. MRSASelect medium held for 24-h incubation is a highly sensitive and specific MRSA-screening tool. Further incubation prolongs the turnaround time for results and creates a significant amount of unnecessary work in the laboratory.


Journal of Antimicrobial Chemotherapy | 2009

Identification of multidrug- and carbapenem-resistant Acinetobacter baumannii in Canada: results from CANWARD 2007

Melissa McCracken; Melanie DeCorby; Jeffrey D. Fuller; Vivian G. Loo; Daryl J. Hoban; George G. Zhanel; Michael R. Mulvey

OBJECTIVESnMultidrug-resistant (MDR) Acinetobacter baumannii is a growing concern in many countries. This report describes patient demographics, antimicrobial susceptibilities and molecular characteristics of A. baumannii cases identified through the Canadian Ward Surveillance Study (CANWARD). In addition, clinical cases involving MDR carbapenem-resistant A. baumannii are also detailed in this report.nnnMETHODSnFrom January to December 2007, 12 hospital centres across Canada submitted pathogens from clinics, emergency rooms, intensive care units and medical/surgical wards as part of the CANWARD study. MICs were determined using microbroth dilution (CLSI). PCR and sequence analysis identified OXA genes among carbapenem-resistant isolates. PFGE was used to determine genetic relatedness and compare representatives of the Midlands 2 strain, OXA-23 clone 1 or 2, T strains and isolates collected from military sources.nnnRESULTSnThis study identified A. baumannii in 0.33% (n = 26) of infections. The majority of isolates remained susceptible to the antimicrobials tested, however, 7.7% (n = 2) displayed an MDR phenotype, including resistance to carbapenems. In one isolate bla(OXA-58) was found to be the likely cause of carbapenem resistance while the other isolate had an insertion sequence element upstream of its intrinsic bla(OXA-51). The clinical data of these two isolates suggest that one is travel-related while the source of the other remains unknown.nnnCONCLUSIONSnA. baumannii infections from Canadian hospitals were relatively low. Carbapenem-resistant MDR A. baumannii were also rare and unrelated to previously observed isolates from military sources. Continued surveillance in Canada is suggested in order to determine if such organisms will become a problem.


Journal of Clinical Microbiology | 2010

Caspofungin Etest Endpoint for Aspergillus Isolates Shows Poor Agreement with the Reference Minimum Effective Concentration

Jeffrey D. Fuller; Adam Schofield; Safeer Jiwa; Crystal Sand; Brad Jansen; Robert Rennie

ABSTRACT The Clinical and Laboratory Standards Institute (CLSI) M38-A2 reference broth microdilution (BMD) method for the antifungal susceptibility testing of filamentous fungi now includes guidelines for testing echinocandin activity using the minimum effective concentration (MEC) as the endpoint measurement. In this study, we compared the caspofungin Etest MIC on RPMI agar and Mueller-Hinton agar (supplemented with glucose and methylene blue [MGM]) to the BMD MEC for 345 clinical Aspergillus isolates, including A. flavus, A. fumigatus, A. nidulans, A. niger, and A. terreus. The essential agreement (±1 log2 dilution) of the Etest on MGM and RPMI agar with the reference BMD MEC was 18 and 26%, respectively. The geometric mean values for BMD MEC and MGM Etest were 0.137 and 0.024 μg/ml, respectively, and the geometric mean values for BMD and RPMI agar were 0.128 and 0.031 μg/ml, respectively. Comparatively, 91% of paired MGM and RPMI Etest results were within 2 log2 dilutions of each other and consistently produced clearly defined endpoints. In conclusion, the caspofungin Etest MIC, like the BMD MEC, is a reproducible endpoint but is markedly lower than the reference BMD. In anticipation of susceptibility breakpoint assignments, optimization studies will be required to improve the concordance of these two assays so that the potential for underreporting echinocandin resistance in Aspergillus is mitigated.


Journal of Clinical Microbiology | 1998

Development of Specific Nested Oligonucleotide PCR Primers for the Streptococcus iniae 16S-23S Ribosomal DNA Intergenic Spacer

Brian R. Berridge; Jeffrey D. Fuller; Joyce de Azavedo; Donald E. Low; Herve Bercovier; Paul F. Frelier


Fems Immunology and Medical Microbiology | 2007

The two‐component system sivS/R regulates virulence in Streptococcus iniae

Shelly Bolotin; Jeffrey D. Fuller; Darrin J. Bast; Joyce de Azavedo

Collaboration


Dive into the Jeffrey D. Fuller's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Michael R. Mulvey

Public Health Agency of Canada

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Victor Nizet

University of California

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrew E. Simor

Sunnybrook Health Sciences Centre

View shared research outputs
Researchain Logo
Decentralizing Knowledge